Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| P30CA093373 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Cancer Institute (NCI) | NIH |
Not provided
Not provided
Not provided
This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.
This is a phase 2 pragmatic study at a single site that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary endpoint is disease control at 3 months, defined as continuation in systemic cancer therapy without any changes or permanent discontinuation for 3 months following first day of ablative local therapy. Participants will receive ablative local therapy per standard practices in addition to their systemic therapy and will be followed for up to 5 years following ablative local therapy. Participants will be assigned stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy per the discretion of treating radiation oncologist and/or interventional radiologist.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ablative local therapy | Experimental | Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ablative local therapy | Device | Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants with controlled disease | Number of participants with controlled disease at 3 months, defined as continuation in systemic cancer therapy without any changes or permanent discontinuation for 3 months following first day of ablative local therapy | 3 months from the first day of ablative local therapy |
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants experiencing grade ≥ 3 adverse events attributable to ablative local therapy | Number of participants experiencing grade ≥ 3 adverse events (except for hematologic and electrolyte abnormalities) attributable to ablative local therapy occurring up to 2 years from the first day of ablative local therapy | Up to 2 years from the first day of ablative local therapy |
Not provided
Inclusion Criteria:
Must have one of the following histologically and/or biochemically confirmed cancers:
Provision of signed and dated informed consent form.
Stated willingness to comply with all study procedures and availability for the duration of the study.
Age ≥18 years at time of consent.
Currently on systemic therapy and a candidate to continue their current line of systemic therapy with no more than a planned 30-day break to allow for local ablative therapy.
≥ 1 line of systemic therapy for metastatic disease with ≥ 3 months of clinical benefit on most recent line of systemic therapy prior to the development of new metastatic lesions. [Clinical benefit: Treating provider assessment that majority of the tumor burden is stable on current systemic treatment and not requiring an immediate change in systemic treatment]
≤ 5 progressing or new metastatic lesions.
All progressing or new metastatic lesions can be safely treated with locally ablative therapies at discretion of treating radiation oncologist and/ interventional radiologist.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Office of Clinical Research | Contact | 916-382-6970 | OCRReferral@health.ucdavis.edu |
| Name | Affiliation | Role |
|---|---|---|
| Edward Kim, MD, PhD | University of California, Davis | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of California, Davis Comprehensive Cancer Center | Recruiting | Sacramento | California | 95817 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Median overall survival | Median overall survival stratified by primary tumor type | Up to 5 years from the first day of ablative local therapy |
| Time to treatment failure | Time to treatment failure, defined as time to change in systemic therapy or permanent discontinuation of cancer therapy | Up to 1 year from the first day of ablative local therapy |
| ID | Term |
|---|---|
| D015179 | Colorectal Neoplasms |
| D001063 | Appendiceal Neoplasms |
| D001661 | Biliary Tract Neoplasms |
| D005706 | Gallbladder Neoplasms |
| D018281 | Cholangiocarcinoma |
| ID | Term |
|---|---|
| D007414 | Intestinal Neoplasms |
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |
| D012002 | Rectal Diseases |
| D002430 | Cecal Neoplasms |
| D002429 | Cecal Diseases |
| D001660 | Biliary Tract Diseases |
| D005705 | Gallbladder Diseases |
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided